Dr. Tania Obranovich has more than 25 years’ experience developing and managing global IP portfolios in the biotechnology sector, in particular in relation to molecular, cellular and genomic technologies as they relate to diagnostics and therapeutics.
She has acquired this experience both through private practice, having spent more than a decade as a partner in a top tier IP firm, and as legal counsel for a US based diagnostics company where she ran patent and trade mark prosecution and drafting, in addition to overseeing all legal, compliance and corporate governance matters. Tania has practiced throughout her career as both a lawyer and patent attorney. Prior to these roles she completed a PhD and post-doctoral fellowship in immunology. In addition to her legal practice, Tania has lectured extensively in patent law at The University of Melbourne and Monash University and also speaks widely in relation to IP issues. She was heavily involved with navigating the Australian and US legal and policy issues that arose as a result of the Myriad gene patent litigation in both these jurisdictions. Tania received a Federal Government appointment to the Professional Standards Board for Patent and TM Attorneys in 2012 and has held several other Board positions.
Tania has served as Chief IP and Legal Strategy Officer to Invivoscribe since 2019.